FOXM1 and central nervous system cancer: A recent clinical trial has highlighted the efficacy of early treatment with a vaccine-based immunotherapy approach using glioma oncoantigens (GOAs) containing FOXM1 before starting chemotherapy or radiotherapy to prevent possible chemo-radio resistance [113].